EGFR and neoplasm: Also, a clinical trial entitled “Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR TKI Therapy (NCT03042221)” will molecularly analyze paired baseline biopsy specimens from advanced stage EGFR mutant lung cancers and biopsies obtained following 2 weeks of EGFR TKI-targeted treatment with the intention to identify early adaptive mechanisms of cell survival in the setting of oncogene-targeted therapy.